Takeda Pharmaceutical (TAK) and Eli Lilly (LLY) will face a multibillion-dollar class action accusing them of concealing diabetes drug Actos' bladder cancer risk after the US Supreme Court rejected their appeal, Bloomberg reported Monday, citing a court order.
The high court rejected the companies' argument that the lawsuit should not go forward as a class action on behalf of tens of thousands of insurers and third-party payers of Actos prescriptions because the plaintiffs provided no viable way of excluding those who did not suffer any harm, according to the report.
Takeda Pharmaceutical and Eli Lilly did not immediately respond to requests for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
